NEW YORK, Nov. 13, 2017 /PRNewswire/ -- If you want a Stock Review on ECYT, EDIT, HALO, or ILMN then come over to http://dailystocktracker.com/register/and sign up for your free customized report. On Friday, November 10, 2017, US markets saw five out of nine sectors finishing the day in red, three in green, and one in neutral territory. Major US indices were mixed at the
On Friday, shares in West Lafayette, Indiana headquartered Endocyte Inc. recorded a trading volume of 1.11 million shares. The stock ended the session 2.90% higher at $5.33. The Company's shares have gained 294.81% over the previous three months, 74.75% in the past twelve months, and 109.02% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 56.82% and 128.95%, respectively. Moreover, shares of Endocyte, which develops targeted therapies for the treatment of cancer and inflammatory diseases in the US, have a Relative Strength Index (RSI) of 65.91. Visit us today and download your complete report on ECYT for free at:
Cambridge, Massachusetts-based Editas Medicine Inc.'s stock closed the day 7.50% higher at $24.38 with a total trading volume of 761,399 shares. The Company's shares have advanced 61.35% over the last twelve months and 50.22% since the start of this year. The stock is trading above its 50-day and 200-day moving averages by 7.37% and 21.87%, respectively. Additionally, shares of Editas Medicine, which operates as a genome editing company, have an RSI of 55.15. The complimentary research report on EDIT can be accessed at:
Shares in San Diego, California headquartered Halozyme Therapeutics Inc. recorded a trading volume of 1.38 million shares. The stock ended last Friday's trading session 2.31% lower at $18.18. The Company's shares have advanced 50.87% over the previous three months, 49.63% in the past twelve months, and 84.01% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 10.34% and 30.62%, respectively. Furthermore, shares of Halozyme Therapeutics, which researches, develops, and commercializes human enzymes and other drug candidates in the US, Switzerland, and internationally, have an RSI of 58.04.
On October 16th, 2017, research firm Piper Jaffray reiterated its 'Overweight' rating on the Company's stock with an increase of the target price from $26 a share to $29 a share. Register for free on DailyStockTracker.com and download the research report on HALO at:
San Diego, California headquartered Illumina Inc.'s stock finished Friday's session 0.32% lower at $208.94 with a total trading volume of 598,594 shares. The Company's shares have advanced 51.00% in the past twelve months and 63.18% since the start of this year. The stock is trading above its 50-day and 200-day moving averages by 1.11% and 13.88%, respectively. Additionally, shares of Illumina, which provides sequencing and array-based solutions for genetic analysis, have an RSI of 50.09.
On October 25th, 2017, research firm Robert W. Baird upgraded the Company's stock rating from 'Neutral' to 'Outperform' while revising its previous target price from $184 a share to $228 a share. Get free access to your research report on ILMN at:
Daily Stock Tracker:
Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
DST has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:Email: email@example.com Phone number: (207)331-3313Office Address: 377 Rivonia Boulevard, Rivonia, South Africa
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
View original content:http://www.prnewswire.com/news-releases/biotech-stocks-on-investors-radar----endocyte-editas-medicine-halozyme-therapeutics-and-illumina-300554456.html
Subscribe to our Free Newsletters!
LADA or Latent Autoimmune Diabetes of Adulthood is a form of type 1 autoimmune diabetes that can be ...
Sleep paralysis is a condition where one feels unable to move (paralysis) or speak either when ...
Summers days are long, hot and sweaty, and can leave you feeling de-hydrated and tired. Read on to ...View All